CTI BioPharma announces top-line results from PERSIST-2 phase 3 trial of Pacritinib
CTI BioPharma announced top-line results from PERSIST-2, a randomized, controlled Phase 3 clinical trial comparing pacritinib, an investigational oral multikinase inhibitor, with physician-specified BAT for treatment of patients with myelofibrosis. August 29, 2016